|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.510 USD | +9.66% |
|
+19.69% | +329.80% |
| 05-07 | ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 05-07 | Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q1 Revenue $44.2M, vs. FactSet Est of $43.1M | MT |
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Revenues | 934K | 240K | 622K | 14.15M | 113M | |||
Other Revenues, Total | - | - | - | 595K | 306K | |||
Total Revenues | 934K | 240K | 622K | 14.74M | 113M | |||
Cost of Goods Sold, Total | - | - | - | - | 753K | |||
Gross Profit | 934K | 240K | 622K | 14.74M | 113M | |||
Selling General & Admin Expenses, Total | 122M | 103M | 135M | 173M | 150M | |||
R&D Expenses | 196M | 248M | 227M | 186M | 219M | |||
Other Operating Expenses, Total | 318M | 351M | 362M | 359M | 369M | |||
Operating Income | -317M | -351M | -361M | -344M | -256M | |||
Interest Expense, Total | -14.85M | -63.52M | -129M | -154M | -113M | |||
Interest And Investment Income | - | - | 1.13M | 7.98M | 6.4M | |||
Net Interest Expenses | -14.85M | -63.52M | -128M | -146M | -106M | |||
Income (Loss) On Equity Invest. | -803K | -12.11M | -7.55M | - | - | |||
Other Non Operating Income (Expenses) | 193K | 16.91M | -84.44M | 77.52M | 10.54M | |||
EBT, Excl. Unusual Items | -333M | -409M | -581M | -413M | -352M | |||
Merger & Related Restructuring Charges | -13M | - | - | - | - | |||
Gain (Loss) On Sale Of Investments | -4.1M | -7.28M | -1.59M | -632K | - | |||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||
Asset Writedown | - | -681K | -886K | - | - | |||
Legal Settlements | - | - | - | - | - | |||
Other Unusual Items | 144K | 51K | -1K | 1K | - | |||
EBT, Incl. Unusual Items | -350M | -417M | -584M | -414M | -352M | |||
Income Tax Expense | 9K | 34K | -40K | - | -135K | |||
Earnings From Continuing Operations | -350M | -417M | -584M | -414M | -351M | |||
Net Income to Company | -350M | -417M | -584M | -414M | -351M | |||
Minority Interest | 3.06M | 753K | 656K | 81K | 74K | |||
Net Income - (IS) | -347M | -417M | -583M | -414M | -351M | |||
Net Income to Common Incl Extra Items | -347M | -417M | -583M | -414M | -351M | |||
Net Income to Common Excl. Extra Items | -347M | -417M | -583M | -414M | -351M | |||
Per Share Items | ||||||||
Net EPS - Basic | -0.89 | -1.04 | -1.15 | -0.59 | -0.38 | |||
Basic EPS - Continuing Operations | -0.89 | -1.04 | -1.15 | -0.59 | -0.38 | |||
Basic Weighted Average Shares Outstanding | 389M | 400M | 509M | 697M | 920M | |||
Net EPS - Diluted | -0.89 | -1.04 | -1.15 | -0.62 | -0.38 | |||
Diluted EPS - Continuing Operations | -0.89 | -1.04 | -1.15 | -0.62 | -0.38 | |||
Diluted Weighted Average Shares Outstanding | 389M | 400M | 509M | 700M | 920M | |||
Normalized Basic EPS | -0.53 | -0.64 | -0.71 | -0.37 | -0.24 | |||
Normalized Diluted EPS | -0.53 | -0.64 | -0.71 | -0.37 | -0.24 | |||
Supplemental Items | ||||||||
EBITDA | -303M | -332M | -343M | -327M | -241M | |||
EBITA | -317M | -351M | -359M | -342M | -254M | |||
EBIT | -317M | -351M | -361M | -344M | -256M | |||
EBITDAR | -292M | -314M | -324M | -308M | -222M | |||
Total Revenues (As Reported) | - | - | - | 14.74M | 113M | |||
Effective Tax Rate - (Ratio) | -0 | -0.01 | 0.01 | - | 0.04 | |||
Current Domestic Taxes | -9K | 38K | -26K | - | 4K | |||
Total Current Taxes | -9K | 38K | -26K | - | 4K | |||
Deferred Domestic Taxes | - | -4K | -14K | - | -139K | |||
Total Deferred Taxes | - | -4K | -14K | - | -139K | |||
Normalized Net Income | -205M | -255M | -363M | -258M | -220M | |||
Interest on Long-Term Debt | - | - | - | 154M | 112M | |||
Supplemental Operating Expense Items | ||||||||
General and Administrative Expenses | - | - | - | - | - | |||
Research And Development Expense From Footnotes | 196M | 248M | 232M | 190M | 219M | |||
Net Rental Expense, Total | 10.84M | 18.03M | 18.73M | 18.5M | 18.58M | |||
Imputed Operating Lease Interest Expense | 2.8M | 13.34M | 24.07M | 27.3M | 20.47M | |||
Imputed Operating Lease Depreciation | 8.04M | 4.69M | -5.33M | -8.8M | -1.89M | |||
Stock-Based Comp., R&D Exp. (Total) | 18.82M | 11.67M | 17.34M | 12M | 10.62M | |||
Stock-Based Comp., G&A Exp. (Total) | - | - | - | - | - | |||
Stock-Based Comp., SG&A Exp. (Total) | 38.36M | 28.51M | 31.82M | 22.43M | 26.19M | |||
Total Stock-Based Compensation | 57.18M | 40.18M | 49.16M | 34.43M | 36.81M |
- Stock Market
- Equities
- IBRX Stock
- Financials ImmunityBio, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















